| Cover | 12 Months Ended |
| Dec. 31, 2022 | |
| Document Information [Line Items] | |
| Document Type | DEF 14A |
| Amendment Flag | false |
| Entity Information [Line Items] | |
| Entity Registrant Name | TRANSMEDICS GROUP, INC. |
| Entity Central Index Key | 0001756262 |
| Pay vs Performance Disclosure - USD ($) | 12 Months Ended | ||
| Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Pay vs Performance Disclosure [Table] | |||
| Pay vs Performance [Table Text Block] | Pay Versus Performance The following table provides the information required for our named executive officers for each of the fiscal years ended December 31, 2022, December 31, 2021, and December 31, 2020 along with the required financial information required for each fiscal year. CAP is calculated in accordance with SEC rules and includes the increase or decrease in value of certain elements of compensation over each fiscal year, including compensation granted in a prior year. CAP does not correlate to the total amount of cash or equity compensation paid or received during each fiscal year. The calculations do not reflect the actual sale of stock underlying equity awards or the exercise of stock options by the executive, and the amount of compensation ultimately received may, in fact, be different from the CAP amounts disclosed in the table below. Year-end value of $100 invested Summary Compensation Average Non-PEO Average Non-PEO Total Peer Group Net Revenue Year $ $ $ $ $ $ $ $ 2022 3,287,862 25,221,430 958,883 4,539,264 324.67 99.81 -36.2 93.5 2021 7,370,365 5,172,911 1,441,564 1,068,071 100.79 125.43 -44.2 30.3 2020 2,385,687 2,664,885 928,500 1,040,799 104.68 130.04 -28.7 25.6 (1) For all years reported, the principal executive officer (“PEO”) was Waleeed Hassanein, M.D., President and Chief Executive Officer. (2) Deductions from, and additions to, total compensation in the Summary Compensation Table (“SCT”) by year to calculate CAP include: 2022 2021 2020 Waleed Average of Non-PEO Waleed Average of Non-PEO Waleed Average of Non-PEO Total Compensation from SCT 3,287,862 958,883 7,370,365 1,441,564 2,385,687 928,500 Total Adjustments for Pension — — — — — — Adjustments for Equity Awards Adjustment for SCT grant date fair value (1,825,900 ) (328,662 ) (6,377,940 ) (977,265 ) (1,445,960 ) (405,485 ) Year-end 10,641,343 1,915,465 2,075,640 318,044 1,671,240 469,456 Year-over-year difference of year-end 8,789,191 1,344,193 (136,022 ) (16,872 ) 67,300 9,331 Fair value at vesting date for awards granted and vested in current year 1,647,831 296,601 949,688 145,504 312,077 87,658 Difference in fair values between prior year-end 2,681,103 352,784 1,291,179 157,096 (325,459 ) (48,661 ) Forfeitures during current year equal to prior year-end — — — — — — Dividends or dividend equivalents not otherwise included in total compensation — — — — — — Total Adjustments for Equity Awards 21,933,568 3,580,381 (2,197,454 ) (373,493 ) 279,198 112,300 Compensation Actually Paid (as calculated) 25,221,430 4,539,264 5,172,911 1,068,071 2,664,885 1,040,799 (3) The following summarizes the valuation assumptions used for stock option awards included as part of CAP: a. Expected life of each stock option is based on the “simplified method” using an average of the remaining vesting period and remaining term, as of the applicable vesting date or fiscal year end. b. Strike price is based on each grant date closing price and asset price is based on the closing price on the applicable vesting date or fiscal year end. c. Risk free rate is based on the Treasury Constant Maturity rate closest to the remaining expected life as of the applicable vesting date or fiscal year end. d. Historical volatility is based on the daily price history for each year of remaining expected life prior to each applicable vesting date or fiscal year end; closing prices are provided by S&P Capital IQ and are adjusted for dividends and splits. e. Represents annual dividend yield on each applicable vesting date or fiscal year end. (4) The folowing table illustrates the valuation assumptions as of the vesting date for awards that vested in each of 2022, 2021 and 2020: For Stock Options Vesting in 2022 2021 2020 Expected volatility 69.15% - 76.30% 64.38% - 72.22% 56.71% - 71.56% Expected dividend yield 0.00% 0.00% 0.00% Expected term, in years 3.2 - 5.0 3.0 - 5.0 3.2 - 5.0 Risk-free interest rate 0.97% - 4.48% 0.19% - 1.34% 0.15% - 1.69% (5) Non-PEO a. 2022: Stephen Gordon (Chief Financial Officer), Tamer Khayal, M.D. (Chief Commercial Officer), Miriam Provost, Ph.D. (Vice President of Global Regulatory Affairs), and Laura Damme (Vice President, Clinical Affairs). b. 2021: Stephen Gordon (Chief Financial Officer), Tamer Khayal, M.D. (Chief Commercial Officer), Miriam Provost, Ph.D. (Vice President of Global Regulatory Affairs), and Laura Damme (Vice President, Clinical Affairs). c. 2020: Stephen Gordon (Chief Financial Officer) and Tamer Khayal, M.D. (Chief Commercial Officer). (6) For purposes of the “Peer group total shareholder return” column of this table, the Nasdaq Healthcare Index (IXHC) was used as our selected peer group. | ||
| Company Selected Measure Name | Revenue | ||
| Named Executive Officers, Footnote [Text Block] | (5) Non-PEO a. 2022: Stephen Gordon (Chief Financial Officer), Tamer Khayal, M.D. (Chief Commercial Officer), Miriam Provost, Ph.D. (Vice President of Global Regulatory Affairs), and Laura Damme (Vice President, Clinical Affairs). b. 2021: Stephen Gordon (Chief Financial Officer), Tamer Khayal, M.D. (Chief Commercial Officer), Miriam Provost, Ph.D. (Vice President of Global Regulatory Affairs), and Laura Damme (Vice President, Clinical Affairs). c. 2020: Stephen Gordon (Chief Financial Officer) and Tamer Khayal, M.D. (Chief Commercial Officer). | ||
| Peer Group Issuers, Footnote [Text Block] | the Nasdaq Healthcare Index (IXHC) was used as our selected peer group. | ||
| PEO Total Compensation Amount | $ 3,287,862 | $ 7,370,365 | $ 2,385,687 |
| PEO Actually Paid Compensation Amount | $ 25,221,430 | 5,172,911 | 2,664,885 |
| Adjustment To PEO Compensation, Footnote [Text Block] | (2) Deductions from, and additions to, total compensation in the Summary Compensation Table (“SCT”) by year to calculate CAP include: 2022 2021 2020 Waleed Average of Non-PEO Waleed Average of Non-PEO Waleed Average of Non-PEO Total Compensation from SCT 3,287,862 958,883 7,370,365 1,441,564 2,385,687 928,500 Total Adjustments for Pension — — — — — — Adjustments for Equity Awards Adjustment for SCT grant date fair value (1,825,900 ) (328,662 ) (6,377,940 ) (977,265 ) (1,445,960 ) (405,485 ) Year-end 10,641,343 1,915,465 2,075,640 318,044 1,671,240 469,456 Year-over-year difference of year-end 8,789,191 1,344,193 (136,022 ) (16,872 ) 67,300 9,331 Fair value at vesting date for awards granted and vested in current year 1,647,831 296,601 949,688 145,504 312,077 87,658 Difference in fair values between prior year-end 2,681,103 352,784 1,291,179 157,096 (325,459 ) (48,661 ) Forfeitures during current year equal to prior year-end — — — — — — Dividends or dividend equivalents not otherwise included in total compensation — — — — — — Total Adjustments for Equity Awards 21,933,568 3,580,381 (2,197,454 ) (373,493 ) 279,198 112,300 Compensation Actually Paid (as calculated) 25,221,430 4,539,264 5,172,911 1,068,071 2,664,885 1,040,799 | ||
| Non-PEO NEO Average Total Compensation Amount | $ 958,883 | 1,441,564 | 928,500 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 4,539,264 | 1,068,071 | 1,040,799 |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | (2) Deductions from, and additions to, total compensation in the Summary Compensation Table (“SCT”) by year to calculate CAP include: 2022 2021 2020 Waleed Average of Non-PEO Waleed Average of Non-PEO Waleed Average of Non-PEO Total Compensation from SCT 3,287,862 958,883 7,370,365 1,441,564 2,385,687 928,500 Total Adjustments for Pension — — — — — — Adjustments for Equity Awards Adjustment for SCT grant date fair value (1,825,900 ) (328,662 ) (6,377,940 ) (977,265 ) (1,445,960 ) (405,485 ) Year-end 10,641,343 1,915,465 2,075,640 318,044 1,671,240 469,456 Year-over-year difference of year-end 8,789,191 1,344,193 (136,022 ) (16,872 ) 67,300 9,331 Fair value at vesting date for awards granted and vested in current year 1,647,831 296,601 949,688 145,504 312,077 87,658 Difference in fair values between prior year-end 2,681,103 352,784 1,291,179 157,096 (325,459 ) (48,661 ) Forfeitures during current year equal to prior year-end — — — — — — Dividends or dividend equivalents not otherwise included in total compensation — — — — — — Total Adjustments for Equity Awards 21,933,568 3,580,381 (2,197,454 ) (373,493 ) 279,198 112,300 Compensation Actually Paid (as calculated) 25,221,430 4,539,264 5,172,911 1,068,071 2,664,885 1,040,799 | ||
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | |||
| Compensation Actually Paid vs. Net Income [Text Block] | |||
| Compensation Actually Paid vs. Company Selected Measure [Text Block] | |||
| Total Shareholder Return Vs Peer Group [Text Block] | |||
| Tabular List [Table Text Block] | Tabular List of Financial Performance Measures As described in greater detail in the CD&A, we have a significant focus on pay-for-performance. non-financial • Revenue; • Financing the business; • Receive FDA approval and/or meet enrollment milestones; and • Expand, maintain, and continue developing current high-quality programs and products. | ||
| Total Shareholder Return Amount | $ 324.67 | 100.79 | 104.68 |
| Peer Group Total Shareholder Return Amount | 99.81 | 125.43 | 130.04 |
| Net Income (Loss) | $ (36,200,000) | $ (44,200,000) | $ (28,700,000) |
| Company Selected Measure Amount | 93,500,000 | 30,300,000 | 25,600,000 |
| PEO Name | Waleeed Hassanein, M.D. | ||
| Measure [Axis]: 1 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Revenue | ||
| Measure [Axis]: 2 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Financing the business | ||
| Measure [Axis]: 3 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Receive FDA approval and/or meet enrollment milestones | ||
| Measure [Axis]: 4 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Expand, maintain, and continue developing current high-quality programs and products | ||
| PEO [Member] | Adjustment for SCT grant date fair value [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ (1,825,900) | $ (6,377,940) | $ (1,445,960) |
| PEO [Member] | Fair Value Of Unvested Awards Granted In The Current Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 10,641,343 | 2,075,640 | 1,671,240 |
| PEO [Member] | Year Over Year Difference of Year End Fair Values for Unvested Awards Granted in Prior Years [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 8,789,191 | (136,022) | 67,300 |
| PEO [Member] | Fair value at vesting date for awards granted and vested in current year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 1,647,831 | 949,688 | 312,077 |
| PEO [Member] | Fair Values Between Prior Year End Fair Values And Vesting Date Fair Values For Awards Granted in Prior Years [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 2,681,103 | 1,291,179 | (325,459) |
| PEO [Member] | Forfeitures during current year equal to prior yearend fair value [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| PEO [Member] | Dividends or dividend equivalents not otherwise included in total compensation [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| PEO [Member] | Total Adjustments for Equity Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 21,933,568 | (2,197,454) | 279,198 |
| PEO [Member] | Total Adjustments for Pension [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| Non-PEO NEO [Member] | Adjustment for SCT grant date fair value [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (328,662) | (977,265) | (405,485) |
| Non-PEO NEO [Member] | Fair Value Of Unvested Awards Granted In The Current Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 1,915,465 | 318,044 | 469,456 |
| Non-PEO NEO [Member] | Year Over Year Difference of Year End Fair Values for Unvested Awards Granted in Prior Years [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 1,344,193 | (16,872) | 9,331 |
| Non-PEO NEO [Member] | Fair value at vesting date for awards granted and vested in current year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 296,601 | 145,504 | 87,658 |
| Non-PEO NEO [Member] | Fair Values Between Prior Year End Fair Values And Vesting Date Fair Values For Awards Granted in Prior Years [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 352,784 | 157,096 | (48,661) |
| Non-PEO NEO [Member] | Forfeitures during current year equal to prior yearend fair value [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| Non-PEO NEO [Member] | Dividends or dividend equivalents not otherwise included in total compensation [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| Non-PEO NEO [Member] | Total Adjustments for Equity Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 3,580,381 | (373,493) | 112,300 |
| Non-PEO NEO [Member] | Total Adjustments for Pension [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ 0 | $ 0 | $ 0 |
